How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

128,667 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Reminiscing on 35 years with Environmental Toxicology in Korea Full Text available with Trip Pro

Reminiscing on 35 years with Environmental Toxicology in Korea 30286587 2018 10 24 2233-6567 33 3 2018 Sep Environmental health and toxicology Environ Health Toxicol Reminiscing on 35 years with Environmental Toxicology in Korea. e2018011-0 10.5620/eht.e2018011 Kim Yong-Hwa YH Department of Chemistry, Faculty of Natural Sciences, National University of Laos, Vientiane Capital, Lao PDR. eng Journal Article 2018 08 31 Korea (South) Environ Health Toxicol 101570455 2233-6567 2018 10 6 6 0 2018 10 (...) 6 6 0 2018 10 6 6 1 ppublish 30286587 eht.e2018011 10.5620/eht.e2018011 PMC6182248

2018 Environmental health and toxicology

102. Increasing knowledge in IGF1R defects: lessons from 35 new patients

Increasing knowledge in IGF1R defects: lessons from 35 new patients Increasing knowledge in IGF1R defects: lessons from 35 new patients | JMG Contact blog by The IGF1R is a keystone of fetal growth regulation by mediating the effects of IGF-I and IGF-II. We detected 21 IGF1R defects in patients with fetal growth restriction, including 8 heterozygous CNVs and 10 heterozygous, 1 homozygous, and 1 compound-heterozygous SNVs. We validated a scoring system based on fetal and post-natal growth (...) retardation, microcephaly and elevated IGF-I levels to identify IGF1R defect. We found a sensitivity of 92% for patients with at least 3 out of 4 criteria. In vitro, we demonstrated an impaired function of the mutated receptors. This functional test is useful to assess pathogenicity of variants of unknown significance, especially with the expansion of nextgeneration sequencing technologies. (By Dr Eloïse Giabicani, ) (Visited 12 times, 1 visits today) Post navigation 23 September 2019 Cancer genetics 23

2019 JMG Contact blog

103. Kinetic study of laboratory mutants of NDM-1 metallo-β-lactamase: the importance of an isoleucine at position 35. Full Text available with Trip Pro

Kinetic study of laboratory mutants of NDM-1 metallo-β-lactamase: the importance of an isoleucine at position 35. Two laboratory mutants of NDM-1 were generated by replacing the isoleucine at position 35 with threonine and serine residues: the NDM-1(I35T)and NDM-1(I35S)enzymes. These mutants were well characterized, and their kinetic parameters were compared with those of the NDM-1 wild type. Thekcat,Km, andkcat/Kmvalues calculated for the two mutants were slightly different from those (...) of the wild-type enzyme. Interestingly, thekcat/Kmof NDM-1(I35S)for loracarbef was about 14-fold higher than that of NDM-1. Far-UV circular dichroism (CD) spectra of NDM-1 and NDM-1(I35T)and NDM-1(I35S)enzymes suggest local structural rearrangements in the secondary structure with a marked reduction of α-helix content in the mutants. Copyright © 2016, American Society for Microbiology. All Rights Reserved.

2016 Antimicrobial Agents and Chemotherapy

104. Hyaluronan 35 kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo Full Text available with Trip Pro

Hyaluronan 35 kDa treatment protects mice from Citrobacter rodentium infection and induces epithelial tight junction protein ZO-1 in vivo Maintaining a healthy intestinal barrier, the primary physical barrier between intestinal microbiota and the underlying lamina propria, is critical for optimal health. Epithelial integrity is essential for the prevention of the entrance of luminal contents, such as bacteria and their products, through the large intestinal barrier. In this study, we (...) protein zonula occludens (ZO)-1 in both healthy and Citrobacter infected mice, as demonstrated by immunoflurorescence and Western blot analyses. Furthermore, we determined that HA35 treatment enhances ZO-1 expression and reduces intestinal permeability at the early stages of dextran sulfate sodium (DSS)-induced colitis in mice. Together, our data demonstrate that the expression and functionality of tight junctions, are increased by HA35 treatment, suggesting a novel mechanism for the protection from

2016 Matrix biology : journal of the International Society for Matrix Biology

105. DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury Full Text available with Trip Pro

DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor (...) on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4+ and CD8+ T cells

2016 Translational stroke research

106. Corrigendum to CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface [Cell Signalling 2016 Sep.; 28(9): 1325–35] Full Text available with Trip Pro

Corrigendum to CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface [Cell Signalling 2016 Sep.; 28(9): 1325–35] 27510742 2018 07 27 1873-3913 28 12 2016 12 Cellular signalling Cell. Signal. Corrigendum to CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface [Cell Signalling 2016 Sep.; 28(9): 1325-35]. 1933 S0898-6568(16)30198-X 10.1016/j.cellsig.2016.07.018 Cypher (...) Biology, & Anatomy, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address: hband@unmc.edu. eng R01 CA087986 CA NCI NIH HHS United States R01 CA144027 CA NCI NIH HHS United States R01 CA099900 CA NCI NIH HHS United States R01 CA099163 CA NCI NIH HHS United States T32 CA009476 CA NCI NIH HHS United States Journal Article Published Erratum 2016 08 07 England Cell Signal 8904683 0898-6568 Cell Signal. 2016 Sep;28(9):1325-35 27224507 2016 8 12 6 0 2016 8 12 6 1 2016 8 12 6 0

2016 Cellular signalling

107. Findings Series 35 - 'Out of School' Foods

of the small area based three-city deprivation measure, has allowed identification of communities in Glasgow which, although almost identical to similar sized areas in Liverpool and Manchester in terms of their socio-economic characteristics, have significantly poorer health outcomes. These will now be the focus for a second, qualitative, phase of research. 2 35 Exploring the Nutritional Quality of ‘Out of School’ Foods Popular with School Pupils 6 Figure 1 FSM Entitlement in Pilot Secondary Schools Source (...) Findings Series 35 - 'Out of School' Foods BRIEFING PAPER September 2010 Investigating a ‘Glasgow Effect’: why do equally deprived UK cities experience different health outcomes? FINDINGS SERIES 25 June 2012 35 Exploring the Nutritional Quality of ‘Out of School’ Foods Popular with School PupilsBRIEFING PAPER FINDINGS SERIES 25 Investigating a ‘Glasgow Effect’: why do equally deprived UK cities experience different health outcomes? KEY FINDINGS % This report summarises a range of analyses

2012 Glasgow Centre for Population Health

108. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

Pooled MM-009 and MM-010 ooled MM-009 and MM-010 trials trials P Petrucci et al. (1989) etrucci et al. (1989) Study design Study design Multinational randomised controlled trial Single-arm trial P Patients in the atients in the trial trial About 35% of patients had 1 prior therapy and about 65% had had at least 2 prior therapies Patients had disease that had relapsed or was refractory to chemotherapy. The number of prior therapies was not reported. Sample size Sample size 353 351 34 Interv (...) Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib L Lenalidomide plus de enalidomide plus dexamethasone for xamethasone for multiple m multiple my yeloma after 1 treatment with eloma after 1 treatment with bortezomib bortezomib T echnology appraisal guidance Published: 26 June 2019 www.nice.org.uk/guidance/ta586 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

109. Five Don'ts to Prevent Novel Coronavirus Infection (COVID-19) and Death - part 1

Five Don'ts to Prevent Novel Coronavirus Infection (COVID-19) and Death - part 1 MED CHECK April 2020/ Vol.6 No.16 · Page C N o 16 M ED HECK 2 0 2 0 Editorial The Plague (La Peste in French) Urgent Recommendations Five Don'ts to Prevent COVID-19 and Death Editorial The Plague (La Peste in French) Urgent Recommendations Five Don'ts to Prevent Novel Coronavirus Infection (COVID-19) and Death 1. Don't use ibuprofen or other NSAIDs 2. Don't use corticosteroids especially in the early phase (...) and remember what happened and to pass that knowledge on to the next generation. Now that many events have been canceled and recreational facilities are closed, why don't you read The Plague? (KIMOTO, Yasusuke) MED CHECK April 2020/ Vol.6 No.16 · Page Five Don'ts to Prevent Novel Coronavirus Infection (COVID-19) and Death Med Check Editorial Team Urgent Recommendations Don’ts (Summary of 5 points) 1.Do not use antipyretics to lower fever. Human body can endure fever at 40-41 ? . Because viruses are weak

2020 Med Check - The Informed Prescriber

110. Bariatric surgery in 1119 patients with preoperative body mass index<35 (kg/m(2)): results at 1 year. (Abstract)

Bariatric surgery in 1119 patients with preoperative body mass index<35 (kg/m(2)): results at 1 year. The use of body mass index (BMI) as the only criterion to indicate bariatric surgery is currently under discussion. There is growing evidence that supports bariatric surgery in carefully selected patients with lower BMI.To report our experience in bariatric surgery in>1000 patients with BMI<35 kg/m(2) and their results at 1 year.University hospital (censored).A retrospective analysis (...) was performed in patients who underwent laparoscopic Roux-en-Y gastric bypass (LRYGB) or sleeve gastrectomy (SG) with preoperative BMI<35 kg/m(2) from January 2008 to December 2011. Demographic and anthropometric data, preoperative co-morbidities, and perioperative variables were retrieved. Weight loss and co-morbidities progression were analyzed 1 year after surgery and compared among procedures. A P value<.05 was considered significant.We identified 1119 patients: mean age 38.8±11.4, 951 (85%) women

2015 Surgery for Obesity and Related Diseases

111. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. Full Text available with Trip Pro

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may circumvent these issues, but there are few data on the safety (...) and immunogenicity of rAd35 directly compared to rAd5 following human vaccination.HVTN 077 randomized 192 healthy, HIV-uninfected participants into one of four HIV-1 vaccine/placebo groups: rAd35/rAd5, DNA/rAd5, and DNA/rAd35 in Ad5-seronegative persons; and DNA/rAd35 in Ad5-seropositive persons. All vaccines encoded the HIV-1 EnvA antigen. Antibody and T-cell responses were measured 4 weeks post boost immunization.All vaccines were generally well tolerated and similarly immunogenic. As compared to rAd5, rAd35

2015 Journal of AIDS & clinical research Controlled trial quality: uncertain

112. β-asarone prevents Aβ25-35-induced inflammatory responses and autophagy in SH-SY5Y cells: down expression Beclin-1, LC3B and up expression Bcl-2 Full Text available with Trip Pro

β-asarone prevents Aβ25-35-induced inflammatory responses and autophagy in SH-SY5Y cells: down expression Beclin-1, LC3B and up expression Bcl-2 Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder. Inflammatory responses and autophagy have been implicated in the amyloid-β (Aβ) aggregation in Alzheimer's disease. Although major evidence indicates that macro autophagy is involved in the pathogenesis of AD, its exact role is still unclear. β-asarone, a major component (...) -asarone could significantly reduce Beclin-1, LC3B and increase anti-apoptotic protein Bcl-2 level. These results showed that β-asarone protected cells from Aβ25-35 induced inflammation and attenuated autophagy via Bcl-2/Beclin-1 pathway. Our findings suggested that β-asarone might be a potential preventive drug for AD.

2015 International journal of clinical and experimental medicine

113. Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway Full Text available with Trip Pro

Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway Vascular response is an essential pathological mechanism underlying various inflammatory diseases. This study determines whether IL-35, a novel responsive anti-inflammatory cytokine, inhibits vascular response in acute inflammation. Using a mouse model of LPS-induced acute inflammation and plasma samples from sepsis patients, we found that IL-35 was induced in the plasma of mice after LPS injection as well (...) as in the plasma of sepsis patients. In addition, IL-35 decreased LPS-induced proinflammatory cytokines and chemokines in the plasma of mice. Furthermore, IL-35 inhibited leukocyte adhesion to the endothelium in the vessels of lung and cremaster muscle and decreased the numbers of inflammatory cells in bronchoalveolar lavage fluid. Mechanistically, IL-35 inhibited the LPS-induced up-regulation of endothelial cell (EC) adhesion molecule VCAM-1 through IL-35 receptors gp130 and IL-12Rβ2 via inhibition

2015 The Journal of biological chemistry

114. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Full Text available with Trip Pro

The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia.Postmenopausal (...) women with primary osteoporosis or osteopenia were randomly assigned to the weekly group or daily group (n=145 for each) that received oral risedronate 35 mg once a week or 5 mg daily, respectively, for 1 year. The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments.All subjects in the weekly group and 144 subjects in the daily group completed the study. The primary efficacy

2015 Acta pharmacologica Sinica Controlled trial quality: predicted high

115. A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β. Full Text available with Trip Pro

A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β. During Ebola virus (EBOV) infection, the type I interferon α/β (IFN-α/β) innate immune response is suppressed by EBOV viral protein 35 (VP35), a validated drug target. Identification of EBOV VP35 inhibitors requires a cellular system able to assess the VP35-based inhibitory functions of viral double

2015 Journal of Infectious Diseases

116. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. Full Text available with Trip Pro

Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. To investigate the potential value of maternal serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 35-37 weeks' gestation in the prediction of delivery of small-for-gestational-age (SGA) neonates, in the absence of pre-eclampsia (PE).This was a screening study in singleton pregnancies at 35-37 weeks, including 158 (...) group, the median PlGF multiples of the median (MoM) was significantly lower and the median sFlt-1 MoM was significantly higher in the SGA group. Combined screening by maternal factors and EFW at 35-37 weeks predicted, at 10% false-positive rate (FPR), 90%, 92% and 94% of SGA neonates with birth weight < 10(th), < 5(th) and < 3(rd) percentiles, respectively, delivering < 2 weeks following assessment; the respective values for SGA delivering ≥ 37 weeks were 66%, 73% and 80%. When PlGF and sFlt-1 were

2015 Ultrasound in Obstetrics and Gynecology

117. HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection Full Text available with Trip Pro

HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection DRα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in DR*1501-Tg mice (...) in a manner similar to the parent DR2β1-containing construct.In order to determine whether DRα1-mMOG-35-55 could treat EAE in major histocompatibility complex (MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation, C57BL/6 mice were treated with DRα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal cords of EAE DR*1501-Tg mice that were treated with DRα1-mMOG-35-55.We here demonstrate that DRα1-mMOG-35-55 could effectively treat EAE

2015 Journal of neuroinflammation

118. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age. (Abstract)

Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age. Alpha-1-antitrypsin (AAT) deficiency is a genetic risk factor for pulmonary emphysema. In 1972-74 all 200,000 Swedish new-born infants were screened for AAT deficiency. The aim of the present study was to investigate whether the PiZZ and PiSZ individuals identified by this screening have signs of emphysema and the role of smoking in this, compared with a random sample (...) of control subjects at 35 years of age. The study participants underwent complete pulmonary function tests (PFT) and CT densitometry. The fifteenth percentile density (PD15) and the relative area below -910 HU (RA-910) were analyzed. Fifty-four PiZZ, 21 PiSZ and 66 PiMM control subjects participated in the study. No significant differences were found in lung function between the never-smoking AAT-deficient and control subjects. The 16 PiZZ ever-smokers had significantly lower carbon monoxide transfer

2015 COPD

119. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. Full Text available with Trip Pro

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B p24, RT, Nef, p17 fusion protein (F4/AS01) plus a non-replicating adenovirus 35 expressing clade A Gag, RT, Int and Nef (Ad35-GRIN) may lead to a unique immune profile (...) , inducing both strong T-cell and antibody responses.In a phase 1, double-blind, placebo-controlled trial, 146 healthy adult volunteers were randomized to one of four regimens: heterologous prime-boost with two doses of F4/AS01E or F4/AS01B followed by Ad35-GRIN; Ad35-GRIN followed by two doses of F4/AS01B; or three co-administrations of Ad35-GRIN and F4/AS01B. T cell and antibody responses were measured.The vaccines were generally well-tolerated, and did not cause serious adverse events. The response

2015 PloS one Controlled trial quality: uncertain

120. Public satisfaction with GP services drops to lowest level in 35 years

Public satisfaction with GP services drops to lowest level in 35 years Public satisfaction with GP services drops to lowest level in 35 years | The King's Fund Main navigation Health and care services Leadership, systems and organisations Patients, people and society Policy, finance and performance Search term Apply Public satisfaction with GP services drops to lowest level in 35 years This content relates to the following topics: Part of Jump link block Jump to section Share this content (...) with other NHS services have not experienced such a steep decline and have tended to fluctuate year on year. And as respondents are more likely to have used GP services rather than the other services covered in the survey, this is likely to be an accurate reflection of their recent experiences. Satisfaction is usually highest among older respondents (Figure 1). For example, in 2017, satisfaction among those aged 65 or older was much higher (77 per cent) than among those aged 18 to 64 (62 per cent

2018 King's Fund blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>